Karuna Therapeutics to Present at Upcoming Investor Conferences
Get Alerts KRTX Hot Sheet
Join SI Premium – FREE
BOSTON--(BUSINESS WIRE)-- Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced that senior management will participate in the following upcoming virtual investor conferences:
William Blair’s Biotech Focus Conference
Date: Thursday, August 6, 2020
Time: 10:00 a.m. EDT
Wedbush PacGrow Healthcare Virtual Conference
Date: Tuesday, August 11, 2020
Time: 10:55 a.m. EDT
Canaccord Genuity 40th Annual Growth Conference
Date: Wednesday, August 12, 2020
Time: 4:00 p.m. EDT
JMP Securities CNS Forum
Date: Wednesday, August 19, 2020
Time: 11:30 a.m. EDT
A live webcast of the Wedbush presentation will be available on the Investor Relations page of Karuna’s website at investors.karunatx.com. A replay of the webcast will also be archived for up to 90 days on Karuna’s website following the conference.
About Karuna
Karuna is a clinical-stage biopharmaceutical company committed to developing and delivering first-in-class therapies with the potential to transform the lives of people with CNS disorders – which remain among the most disabling and potentially fatal disorders worldwide. Galvanized by the understanding that today’s neuropsychiatric and pain management patients deserve better, Karuna’s mission is to harness the untapped potential of the brain’s complex biology in pursuit of novel therapeutic pathways that will advance the standard of care. For more information, please visit karunatx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200730005169/en/
Investor Contact
Alexis Smith
518-338-8990
[email protected]
Source: Karuna Therapeutics, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays
- Canada's Drug Agency issues final positive recommendation supporting public reimbursement of Leqembi®
- Ripple and SettleMint partner to provide digital asset custody and tokenization for financial institutions in Asia Pacific
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
William Blair, JMP Securities, Canaccord GenuitySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share